Awareness of hypertension induced by antineoplastic agents largely arose following the introduction of vascular endothelial growth factor inhibitors (VEGFI), which are associated with hypertension in a large proportion of treated individuals.5 Additionally, many other commonly used antineoplastic agents have been associated with an increase in blood pressure and either de novo hypertension or a deterioration of previously well-controlled hypertension. Here, VEGFA is linked to Hypertension.